Brokerages Expect Prothena Co. PLC (PRTA) to Announce -$1.44 EPS
Equities research analysts predict that Prothena Co. PLC (NASDAQ:PRTA) will report ($1.44) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Prothena’s earnings. The lowest EPS estimate is ($1.55) and the highest is ($1.36). Prothena reported earnings of ($1.41) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 2.1%. The firm is scheduled to announce its next earnings results on Tuesday, February 13th.
According to Zacks, analysts expect that Prothena will report full-year earnings of ($4.27) per share for the current fiscal year, with EPS estimates ranging from ($4.39) to ($4.20). For the next financial year, analysts expect that the firm will report earnings of ($5.21) per share, with EPS estimates ranging from ($6.26) to ($3.95). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Prothena.
Prothena (NASDAQ:PRTA) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.41) by $0.04. The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.28 million. Prothena had a negative return on equity of 34.40% and a negative net margin of 562.19%. The firm’s quarterly revenue was down 33.6% compared to the same quarter last year. During the same quarter last year, the company earned ($1.26) earnings per share.
Institutional investors have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. increased its stake in shares of Prothena by 6.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 163,681 shares of the biotechnology company’s stock valued at $8,859,000 after purchasing an additional 9,824 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Prothena by 16.2% in the 2nd quarter. SG Americas Securities LLC now owns 4,064 shares of the biotechnology company’s stock valued at $220,000 after purchasing an additional 568 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Prothena by 7.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 185,462 shares of the biotechnology company’s stock valued at $10,037,000 after purchasing an additional 13,492 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Prothena by 8.9% in the 2nd quarter. Legal & General Group Plc now owns 13,708 shares of the biotechnology company’s stock valued at $740,000 after purchasing an additional 1,120 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its stake in shares of Prothena by 144.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 6,858 shares of the biotechnology company’s stock valued at $371,000 after purchasing an additional 4,051 shares during the last quarter.
Shares of Prothena (NASDAQ PRTA) traded down $1.38 during midday trading on Tuesday, hitting $39.95. The stock had a trading volume of 576,260 shares, compared to its average volume of 356,070. The company has a market capitalization of $1,589.01, a price-to-earnings ratio of -9.44 and a beta of 2.43. Prothena has a one year low of $34.85 and a one year high of $70.00.
ILLEGAL ACTIVITY NOTICE: “Brokerages Expect Prothena Co. PLC (PRTA) to Announce -$1.44 EPS” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/16/brokerages-expect-prothena-co-plc-prta-to-announce-1-44-eps.html.
Prothena Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.